Because our previous study showed that the expression of gankyrin positively associates with the targeted drug resistance in RCC10, we also investigated the involvement of gankyrin in the resistance of ccRCC to the first-line targeted drug pazopanib. The gene discussed is PSMD10; the disease is nonpapillary renal cell carcinoma.